Key findings from detailed records
Small trials of moringa leaf powder have produced different glucose findings. Recent syntheses do not establish a consistent, high-certainty cardiometabolic benefit.
KNOWLEDGE RECORD
- Category
- Metabolism and cellular function
- Last Reviewed
- 2026-09-27
Names and related search termsMoringa oleifera; drumstick tree; moringa leaf powder
OUTCOME-SPECIFIC EVIDENCE
Scientific Evidence Profile
Assessment pending
An outcome-specific assessment has not yet been completed. This is not a finding that the ingredient is ineffective. The study records below remain available.
This profile concerns the stated outcome and population, not the ingredient as a whole. It is not a probability of benefit, a safety rating, a product efficacy rating or an indication of product adoption.
How we assess evidenceIngredient Profile
- What material is being studied?
- Moringa leaf powder and leaf infusions are different preparations. Composition testing identifies nutrients and polyphenols; findings from animal safety experiments cannot be converted directly into a human dose. [1]
Sources for this profile
Compound properties and formulation properties are different. These sources do not establish the efficacy of a finished supplement.
- Evaluation of acute toxicity, 28-day repeated dose toxicity, and genotoxicity of Moringa oleifera leaves infusion and powder. Identity and preparation checked against the study abstract. Funding details are not verified for this profile source. Conflict-of-interest details are not verified here.
Profile sources checked:
Read the evidence in context
- Evidence: what was measured in the stated population or experimental model.
- Inference: an interpretation connecting findings; its applicability depends on the study conditions.
- Hypothesis: a proposed explanation or effect that remains to be tested.
Why It Matters #
Moringa oleifera is eaten as food in several regions and is also sold as leaf powder or extracts. Leaves contain nutrients, fiber and phytochemicals, but the amount delivered depends on the portion and processing. Traditional use and laboratory activity can motivate a trial; they do not settle its result. Leaf-powder evidence should not be extended to roots, bark or every extract.
What Was Studied #
A Spanish trial studied 2.4 g/day of dry leaf powder for 12 weeks in prediabetes. A smaller Thai trial used 8 g/day for four weeks in untreated type 2 diabetes. Differences in baseline metabolic status, duration and preparation make these more than a simple dose comparison.[2][3]
What Was Found #
The prediabetes study found favorable between-group changes in fasting glucose and HbA1c, without differences in the measured microbiota, appetite hormones or liver and kidney markers. The four-week diabetes trial found no significant glucose-control advantage.[2][3]
A 2025 synthesis of nine randomized trials rated the evidence very low certainty and found no robust overall effect on most cardiometabolic outcomes. A 2026 blood-pressure/weight synthesis reported a systolic-pressure benefit, illustrating how study selection and endpoints can alter pooled conclusions.[1][6]
What the Evidence Means #
There are human signals worth testing, but broad claims about metabolic protection exceed the consistency of the evidence. Secondary publications from the same prediabetes trial do not constitute independent replication. Neither a traditional food history nor small short-term laboratory safety findings establish the safety of every concentrated extract.[4]
What We Can Learn #
Compare the plant part, powder versus extract, daily mass and baseline glucose status. A study of leaf powder in prediabetes does not establish an effect of a standardized extract in healthy adults. Read the synthesis alongside the actual trials rather than using one favorable pooled endpoint as the conclusion for the whole plant.
What Remains Unknown #
The most useful next evidence would be independent replication of the prediabetes findings, with a defined preparation and enough follow-up to assess progression or sustained glycemic control. Long-term safety and the relative contribution of nutrients, fiber and specific phytochemicals remain insufficiently characterized.
LITERATURE MAP / 10 PAPERS
Compare papers by conditions and findings.
Compare populations, preparations, doses and outcomes. Detailed records below assess selected studies; the remaining entries provide a bibliographic route into related questions.
Selected: 2026-09-27. Bibliographic information checked against Europe PMC / PubMed. This editorial selection includes major trials, evidence syntheses and different research questions; it is not an exhaustive systematic review. Paper counts are not counts of independent trials.
10 RECORDS
A dash marks fields not assessed in a bibliographic-only record.
| Paper and topic | Study conditions | Findings and scope |
|---|---|---|
| Detailed recordEffects of Moringa oleifera Lam. Supplementation on Cardiometabolic Outcomes: A Meta-Analysis of Randomized Controlled Trials with GRADE Assessment.PMID 41305552 # | Study conditions Systematic review and meta-analysis of randomized trials
| Findings and scope Most pooled outcomes were not significant. A diastolic-pressure signal was not robust in sensitivity analyses; certainty was very low. Read detailed record |
| Detailed recordMoringa oleifera Leaf Supplementation as a Glycemic Control Strategy in Subjects with Prediabetes.PMID 35010932 # | Study conditions Randomized, double-blind, placebo-controlled parallel trial
| Findings and scope Fasting glucose and HbA1c changes favored moringa. Measured microbiota, appetite hormones and hepatic/renal markers did not differ between groups. Read detailed record |
| Detailed recordEffect of Moringa oleifera Leaf Capsules on Glycemic Control in Therapy-Naïve Type 2 Diabetes Patients: A Randomized Placebo Controlled Study.PMID 29317895 # | Study conditions Randomized, placebo-controlled trial
| Findings and scope Glucose control did not improve significantly versus placebo. Transient diarrhea was reported by 4 of 16 moringa recipients; no hypoglycemia or adverse change in measured liver/kidney markers was reported. Read detailed record |
| Effects of Moringa oleifera Lam. Supplementation on Inflammatory and Cardiometabolic Markers in Subjects with Prediabetes.PMID 35565903 # | Study conditions — | Findings and scope — Open original paperSecondary report from the prediabetes trial represented by PMID 35010932. |
| Effects of Moringa oleifera leaves on the blood glucose, blood pressure, and lipid profile of type 2 diabetic subjects: A parallel group randomized clinical trial of efficacy.PMID 37229639 # | Study conditions — | Findings and scope — Open original paper |
| The Effect of Moringa oleifera on Body Weight and Blood Pressure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.PMID 42254443 # | Study conditions — | Findings and scope — Open original paper |
| Moringa oleifera on hyperglycemia and hypertension in metabolic diseases: Systematic review, exploratory meta-analysis and meta-regression.PMID 41816507 # | Study conditions — | Findings and scope — Open original paper |
| The impact of Moringa oleifera leaf supplementation on human and animal nutrition, growth, and milk production: A systematic review.PMID 35302264 # | Study conditions — | Findings and scope — Open original paper |
| Effects of Moringa oleifera supplementation on immune and nutritional biomarkers in adults living with HIV: a systematic review and meta-analysis.PMID 40989801 # | Study conditions — | Findings and scope — Open original paper |
| The effect of Moringa oleifera capsule in increasing breast milk volume in early postpartum patients: A double-blind, randomized controlled trial.PMID 36440058 # | Study conditions — | Findings and scope — Open original paper |
No papers match. Change the search conditions.
Explore the research Study Records
Listed doses describe study conditions, not recommended intake.
Moringa oleifera Leaf Supplementation as a Glycemic Control Strategy in Subjects with Prediabetes.
PubMed 35010932 DOI: 10.3390/nu14010057
- Authors
- Gómez-Martínez S, Díaz-Prieto LE, Vicente Castro I, Jurado C, Iturmendi N, Martín-Ridaura MC, Calle N, Dueñas M, Picón MJ, Marcos A, Nova E.
- Journal
- Nutrients
- Publication year
- 2021
- Study design
- Randomized, double-blind, placebo-controlled parallel trial
- Participants
- 73 adults with prediabetes randomized; 65 completed (31 moringa, 34 placebo)
- Dose and intervention
- Dry M. oleifera leaf powder 2,400 mg/day in six capsules versus placebo
- Duration
- 12 weeks
- Outcomes and their role in the study
- Fasting glucose, HbA1c, appetite hormones, microbiota and safety laboratories
- Findings
- Fasting glucose and HbA1c changes favored moringa. Measured microbiota, appetite hormones and hepatic/renal markers did not differ between groups.
- Limitations
- Small study; incomplete follow-up; biomarker rather than diabetes-incidence outcome.
- Funding
- Supported by Spanish MCIN/AEI and ERDF funding for project AGL2017-86044-C2-1-R.
- Conflict of Interest
- The authors declared no conflicts of interest.
- What We Can Learn
- A defined leaf-powder preparation produced a glycemic signal requiring replication.
- Scope of source review
- Original full text and bibliographic record reviewed.
Effect of Moringa oleifera Leaf Capsules on Glycemic Control in Therapy-Naïve Type 2 Diabetes Patients: A Randomized Placebo Controlled Study.
PubMed 29317895 DOI: 10.1155/2017/6581390
- Authors
- Taweerutchana R, Lumlerdkij N, Vannasaeng S, Akarasereenont P, Sriwijitkamol A.
- Journal
- Evidence-based complementary and alternative medicine : eCAM
- Publication year
- 2017
- Study design
- Randomized, placebo-controlled trial
- Participants
- 32 adults with therapy-naïve type 2 diabetes; all completed
- Dose and intervention
- 4 g leaf powder before breakfast and 4 g before dinner (8 g/day) versus matched placebo
- Duration
- 4 weeks
- Outcomes and their role in the study
- Fasting, premeal and postmeal glucose; HbA1c; safety markers
- Findings
- Glucose control did not improve significantly versus placebo. Transient diarrhea was reported by 4 of 16 moringa recipients; no hypoglycemia or adverse change in measured liver/kidney markers was reported.
- Limitations
- Short duration, especially for HbA1c; small sample; cannot exclude less common harms.
- Funding
- Not verified in the source material available for this record.
- Conflict of Interest
- Authors declared no conflicts of interest.
- What We Can Learn
- A larger daily mass did not establish benefit in this different population.
- Scope of source review
- Original full text and bibliographic record reviewed.
Effects of Moringa oleifera Lam. Supplementation on Cardiometabolic Outcomes: A Meta-Analysis of Randomized Controlled Trials with GRADE Assessment.
PubMed 41305552 DOI: 10.3390/nu17223501
- Authors
- Crișan D, Gavrilaș L, Păltinean R, Frumuzachi O, Mocan A, Crișan G.
- Journal
- Nutrients
- Publication year
- 2025
- Study design
- Systematic review and meta-analysis of randomized trials
- Participants
- Nine trials, 12 intervention arms; 649 participants
- Dose and intervention
- Moringa preparations versus control; regimens varied
- Duration
- Trial durations varied
- Outcomes and their role in the study
- Weight, lipids, glycemia and blood pressure
- Findings
- Most pooled outcomes were not significant. A diastolic-pressure signal was not robust in sensitivity analyses; certainty was very low.
- Limitations
- Small heterogeneous trials, preparation differences and sensitivity to included studies.
- Funding
- No external research funding reported; university publication support.
- Conflict of Interest
- The authors declared no conflicts of interest.
- What We Can Learn
- The positive individual studies do not yet produce a stable overall estimate.
- Scope of source review
- Original full text and bibliographic record reviewed.
Cite this page
LÍFSVARÐA. Moringa: How consistent are human metabolic findings? Version 1.0 / Updated 2026-10-24
https://lifsvarda.com/knowledge/moringa/Edited by LÍFSVARÐA (product brand). Editorial policy
Primary Sources and updates
- Crișan D, Gavrilaș L, Păltinean R, Frumuzachi O, Mocan A, Crișan G. (2025). Effects of Moringa oleifera Lam. Supplementation on Cardiometabolic Outcomes: A Meta-Analysis of Randomized Controlled Trials with GRADE Assessment. Nutrients DOI: 10.3390/nu17223501Original full text and bibliographic record reviewed.
- Gómez-Martínez S, Díaz-Prieto LE, Vicente Castro I, Jurado C, Iturmendi N, Martín-Ridaura MC, Calle N, Dueñas M, Picón MJ, Marcos A, Nova E. (2021). Moringa oleifera Leaf Supplementation as a Glycemic Control Strategy in Subjects with Prediabetes. Nutrients DOI: 10.3390/nu14010057Original full text and bibliographic record reviewed.
- Taweerutchana R, Lumlerdkij N, Vannasaeng S, Akarasereenont P, Sriwijitkamol A. (2017). Effect of Moringa oleifera Leaf Capsules on Glycemic Control in Therapy-Naïve Type 2 Diabetes Patients: A Randomized Placebo Controlled Study. Evidence-based complementary and alternative medicine : eCAM DOI: 10.1155/2017/6581390Original full text and bibliographic record reviewed.
- Díaz-Prieto LE, Gómez-Martínez S, Vicente-Castro I, Heredia C, González-Romero EA, Martín-Ridaura MDC, Ceinos M, Picón MJ, Marcos A, Nova E. (2022). Effects of Moringa oleifera Lam. Supplementation on Inflammatory and Cardiometabolic Markers in Subjects with Prediabetes. Nutrients DOI: 10.3390/nu14091937Bibliographic record; not a detailed study appraisal.
- C Afiaenyi I, K Ngwu E, M Okafor A, Ayogu RN. (2025). Effects of Moringa oleifera leaves on the blood glucose, blood pressure, and lipid profile of type 2 diabetic subjects: A parallel group randomized clinical trial of efficacy. Nutrition and health DOI: 10.1177/02601060231176873Bibliographic record; not a detailed study appraisal.
- Samarin MM, Sheikhhossein F, Khalilkhaneh AH, Ghaemi S, Abbasi A, Bazyar H, Djafari F, Dianati Z, Khodashenas SM, Askari G, Amini MR. (2026). The Effect of Moringa oleifera on Body Weight and Blood Pressure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Food science & nutrition DOI: 10.1002/fsn3.71899Bibliographic record; not a detailed study appraisal.
- Mokgalaboni K, Ahmed SR, Phoswa WN, Mashaba GR, Mokgalabone TT, Ndhlala AR, Mpai S, Lebelo SL. (2026). Moringa oleifera on hyperglycemia and hypertension in metabolic diseases: Systematic review, exploratory meta-analysis and meta-regression. Metabolism open DOI: 10.1016/j.metop.2026.100451Bibliographic record; not a detailed study appraisal.
- Brar S, Haugh C, Robertson N, Owuor PM, Waterman C, Fuchs GJ, Attia SL. (2022). The impact of Moringa oleifera leaf supplementation on human and animal nutrition, growth, and milk production: A systematic review. Phytotherapy research : PTR DOI: 10.1002/ptr.7415Bibliographic record; not a detailed study appraisal.
- Jin D, Jin S, Zhou T, Sheng G, Gao P, Li G. (2025). Effects of Moringa oleifera supplementation on immune and nutritional biomarkers in adults living with HIV: a systematic review and meta-analysis. Frontiers in nutrition DOI: 10.3389/fnut.2025.1667158Bibliographic record; not a detailed study appraisal.
- Fungtammasan S, Phupong V. (2022). The effect of Moringa oleifera capsule in increasing breast milk volume in early postpartum patients: A double-blind, randomized controlled trial. European journal of obstetrics & gynecology and reproductive biology: X DOI: 10.1016/j.eurox.2022.100171Bibliographic record; not a detailed study appraisal.
First published: 2026-09-27 / Version 1.0. Sources reviewed 2026-09-27. Funding and conflicts are recorded separately; an unverified disclosure is not a declaration of no funding or no conflict.